Free Alerts   Login
Health Care › Electronic Computers

OMCL Stock Price Correlated With Omnicell Financials

OMCL Stock Price vs. Quarterly
OMCL
Income Statement
Cash Flow
Balance Sheet

OMCL Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

OMCL Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

OMCL Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock.
7,887,234 sh
26,144 sh
0%
$296,798
-$57,265
Vanguard Group
5,571,420 sh
434,336 sh
8%
$209,653
-$21,721
State Street
2,012,411 sh
133,822 sh
7%
$75,727
-$8,885
Champlain Investment Partners
1,511,970 sh
-72,450 sh
-5%
$56,895
-$14,467
Clearbridge Investments
1,185,967 sh
-148,916 sh
-11%
$44,628
-$15,495
Morgan Stanley
1,180,745 sh
211,900 sh
22%
$44,431
$794
Bank Of New York Mellon
1,165,628 sh
-125,233 sh
-10%
$43,863
-$14,277
Dimensional Fund Advisors
1,067,516 sh
21,798 sh
2%
$40,173
-$6,927
Pacer Advisors.
1,058,027 sh
1,057,698 sh
321489%
$39,814
$39,799
Geode Capital Management
997,689 sh
51,584 sh
5%
$37,547
-$5,071
Geneva Capital Management
938,944 sh
-41,590 sh
-4%
$35,332
-$8,831
Macquarie Group
893,499 sh
108,337 sh
14%
$33,622
-$1,742
D. E. Shaw & Co..
703,631 sh
210,961 sh
43%
$26,478
$4,288
Arrowmark Colorado Holdings
703,120 sh
139,669 sh
25%
$26,458
$1,080
Credit Suisse Ag
680,058 sh
-378,233 sh
-36%
$25,590
-$22,076
Mirae Asset Global Investments Co.,.
638,646 sh
19,601 sh
3%
$24,032
-$3,849
Royal Bank Of Canada
597,686 sh
64,965 sh
12%
$22,491
-$1,502
Legal & General Group Plc
567,083 sh
156,734 sh
38%
$21,340
$2,858
Exchange Traded Concepts
566,704 sh
184,213 sh
48%
$21,325
$4,098
Northernrp
540,514 sh
8,933 sh
2%
$20,339
-$3,604
COMPANY PROFILE
Organization and Summary of Significant Accounting Policies Business

Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products and related services are medication management solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” collectively refer to Omnicell, Inc. and its subsidiaries.

Basis of Presentation

The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s consolidated financial position, results of operations, and cash flows for the periods presented.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

On September 9, 2021, the Company completed its acquisition of RxInnovation Inc., operating as FDS Amplicare (“FDS Amplicare”); on December 29, 2021, the Company completed its acquisition of ReCept Holdings, Inc. (“ReCept”); and on December 31, 2021, the Company completed its acquisition of MarkeTouch Media, LLC (“MarkeTouch Media”). The Consolidated Financial Statements include the results of operations of these recently acquired companies, commencing as of the respective acquisition dates. The significant accounting policies of the acquired businesses have been aligned to conform to the accounting policies of Omnicell.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. Those policies are revenue recognition; allowance for credit losses for accounts receivable and unbilled receivables; notes receivable from investment in sales-type leases; operating lease right-of-use assets and liabilities; inventory valuation; capitalized software development costs; impairment of goodwill; purchased intangibles and long-lived assets; fair value of assets acquired and liabilities assumed in business combinations; convertible senior notes; share-based compensation; and accounting for income taxes. As of December 31, 2021, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities.

Segment Reporting

The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.

Foreign Currency Translation and Remeasurement

Most of the Company’s foreign subsidiaries use the local currency of their respective countries as their functional curren

Free historical financial statements for Omnicell Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 48 quarters since 2012. Compare with OMCL stock chart to see long term trends.

Data imported from Omnicell Inc SEC filings. Check original filings before making any investment decision.